Design, synthesis, molecular modeling and anticholinesterase activity of benzylidene-benzofuran-3-ones containing cyclic amine side chain

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron 44(1), 181–193 (2004).
  Medline CASGoogle Scholar
• 2 Ballard C, Gaulthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet 377(9770), 1019–1031 (2011).
  MedlineGoogle Scholar
• 3 Becker RE, Greig NH, Giacobini E, Schneider LS, Ferrucci L. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13(2), 140–156 (2014).
  MedlineGoogle Scholar
• 4 Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science 314(5800), 777–781 (2006).
  Medline CASGoogle Scholar
• 5 Tang H, Zhao HT, Zhong SM, Wang ZY, Chen ZF, Liang H. Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. Bioorg. Med. Chem. Lett. 22(6), 2257–2261 (2012).
  Medline CASGoogle Scholar
• 6 Jacobsen JS, Reinhart P, Pangalos MN. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer’s disease. NeuroRx 2(4), 612–626 (2005). •• Focuses on the introduction of acetylcholinesterase and its role in Alzheimer’s disease.
  MedlineGoogle Scholar
• 7 Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol. 2(9), 539–547 (2003).
  Medline CASGoogle Scholar
• 8 Alvarez A, Bronfman F, Perez CA, Vicente M, Garrido J, Inestrosa NC. Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-beta-peptides. Neurosci. Lett. 201(1), 49–52 (1995).
  Medline CASGoogle Scholar
• 9 Carreiras MC, Marco JL. Recent approaches to novel anti-Alzheimer therapy. Curr. Pharm. Des. 10(25), 3167–3175 (2004).
  Medline CASGoogle Scholar
• 10 Bores GM, Huger FP, Petko W et al. Pharmacological evaluation of novel Alzheimer’s disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J. Pharmacol. Exp. Ther. 277(2), 728–738 (1996).
  Medline CASGoogle Scholar
• 11 Wiesner J, Kriz Z, Kuca K, Jun D, Koča J. Acetylcholinesterases – the structural similarities and differences. J. Enzyme Inhib. Med. Chem. 22(4), 417–424 (2007).
  Medline CASGoogle Scholar
• 12 Repantis D, Laisney O, Heuser I. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol. Res. 61(6), 473–481 (2010).
  Medline CASGoogle Scholar
• 13 Schneider LS. Critical review of cholinesterase inhibitors as a treatment modality in Alzheimer’s disease. Dialogues Clin. Neurosci. 2(2), 111–128 (2000).
  MedlineGoogle Scholar
• 14 Forette F, Anand R, Gharabawi G. A Phase II study in patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur. J. Neurol. 6(4), 423–429 (1999).
  Medline CASGoogle Scholar
• 15 Zemek F, Drtinova L, Nepovimova E et al. Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin. Drug Saf. 13(6), 759–774 (2014).
  Medline CASGoogle Scholar
• 16 Castro A, Martinez A. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer’s disease. Mini Rev. Med. Chem. 1(3), 267–272 (2001). • Focuses on the importance and biological activities of homoisoflavonoids.
  Medline CASGoogle Scholar
• 17 Lee H, Yuan Y, Rhee I, Corson TW, Seo SY. Synthesis of natural homoisoflavonoids having either 5,7-dihydroxy-6-methoxy or 7-hydroxy-5-6-dimethoxy groups. Molecules 21(8), 1058–1067 (2016).
  Google Scholar
• 18 Alali F, Ell-Elimat T, Albataineh H et al. Cytotoxic homoisoflavonoides from the blubs of Bellevalia eigii. J. Nat. Prod. 78(7), 1708–1715 (2015).
  Medline CASGoogle Scholar
• 19 Li Y, Qiang X, Luo L et al. Multitarget drug design strategy against Alzheimer’s disease: homoisoflavonoid mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties. Bioorg. Med. Chem. 25(2), 714–726 (2017).
  Medline CASGoogle Scholar
• 20 Lee B, Sun W, Lee H et al. Design, synthesis and biological evaluation of photoaffinity probes of antiangiogenic homoisoflavonoids. Bioorg. Med. Chem. Lett. 26(17), 4277–4281 (2016).
  Medline CASGoogle Scholar
• 21 Xu X, Cheng K, Cheng W, Zhou T, Jiang M, Xu J. Isolation and chatacterization of homoisoflavonoids from Dracaena cochinchinensis and their osteogenic activities in mouse mesenchymalstem cells. J. Pharm. Biomed. Anal. 129, 466–472 (2016).
  Medline CASGoogle Scholar
• 22 Toit KD, Drewes SE, Bodenstein J. The chemical structures, plant origins, ethno botany and biological activities of homoisoflavanones. Nat. Prod. Res. 24(5), 457–490 (2010).
  MedlineGoogle Scholar
• 23 Razavi SF, Khoobi M, Nadri H et al. Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase. Eur. J. Med. Chem. 64, 252–259 (2013).
  Medline CASGoogle Scholar
• 24 Alipour M, Khoobi M, Foroumadi A et al. Novel coumarin derivatives bearing N-benzyl pyridinium moiety: potent and dual binding site acetylcholinesterase inhibitors. Bioorg. Med. Chem. 20(24), 7214–7222 (2012).
  Medline CASGoogle Scholar
• 25 Asadipour A, Alipour M, Jafari M et al. Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors. Eur. J. Med. Chem. 70, 623–630 (2013).
  Medline CASGoogle Scholar
• 26 Ghanei-Nasab S, Khoobi M, Hadizadeh F et al. Synthesis and anticholinesterase activity of coumarin-3-carboxamides bearing tryptamine moiety. Eur. J. Med. Chem. 121, 40–46 (2016).
  Medline CASGoogle Scholar
• 27 Pourshojaei Y, Gouranourimi A, Hekmat S et al. Design, synthesis and anticholinesterase activity of novel benzylidenechroman-4-ones bearing cyclic amine side chain. Eur. J. Med. Chem. 97, 181–189 (2015).
  Medline CASGoogle Scholar
• 28 Luo Z, Liang L, Sheng J et al. Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer’s disease. Bioorg. Med. Chem. 22(4), 1355–1361 (2014).
  Medline CASGoogle Scholar
• 29 Taylor KM, Taylor ZE, Handy ST. Rapid synthesis of aurones under mild conditions using a combination of microwaves and deep eutectic solvents. Tetrahedron Lett. 58, 240–241 (2017).
  CASGoogle Scholar
• 30 Lee YH, Shin MC, Yun YD et al. Synthesis of aminoalkyl-substituted aurone derivatives as acetylcholinesterase inhibitors. Bioorg. Med. Chem. 23(1), 231–240 (2015).
  Medline CASGoogle Scholar
• 31 Nadri H, Pirali-Hamedani M, Shekarchi M et al. Design, synthesis and anticholinesterase activity of a novel series of 1-benzyl-4-((6-alkoxy-3-oxobenzofuran-2(3H)-ylidene) methyl) pyridinium derivatives. Bioorg. Med. Chem. 18(17), 6360–6366 (2010).
  Medline CASGoogle Scholar
• 32 Nagarapu L, Aneesa S, Satyender A, Chandana G, Bantu R. Synthesis and antimicrobial activity of novel analogs of trifenagrel. J. Heterocycl. Chem. 46(2), 195–200 (2009).
  CASGoogle Scholar
• 33 Zhou Y, Shuai L, Weng X, Zhou X, Yang G. Bisbenzimidazole to benzobisimidazole: from binding B-form duplex DNA to recognizing different modes of telomereG-quadruplex. Chem. Commun. 8, 902–904 (2009).
  Google Scholar
• 34 Foroumadi A, Samzadeh-Kermani A, Emami S et al. Synthesis and antioxidant properties of substituted 3-benzylidene-7-alkoxychroman-4-ones. Bioorg. Med. Chem. Lett. 17(24), 6764–6769 (2007).
  Medline CASGoogle Scholar
• 35 Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7(2), 88–95 (1961).
  Medline CASGoogle Scholar
• 36 Alipour M, Khoobi M, Nadri H et al. Synthesis of some new 3-coumaranone and coumarin derivatives as dual inhibitors of acetyl- and butyrylcholinesterase. Arch. Pharm. 346(8), 577–587 (2013).
  Medline CASGoogle Scholar
• 37 Mohammadi-Khanaposhtani M, Saeedi M, Zafarghandi NS et al. Potent acetylcholinesterase inhibitors: design, synthesis, biological evaluation, and docking study of acridone linked to 1,2,3-triazole derivatives. Eur. J. Med. Chem. 92, 799–806 (2015).
  Medline CASGoogle Scholar
• 38 admetSAR. http://lmmd.ecust.edu.cn:8000/predict
  Google Scholar
• 39 Molinspiration Cheminformatics. www.molinspiration.com
  Google Scholar
• 40 Cheng F, Li W, Zhou Y et al. admetSAR: a comprehensive source and free tool for evaluating chemical ADMET properties. J. Chem. Inf. Model. 52(11), 3099–3105 (2012).
  Medline CASGoogle Scholar
• 41 Aslanian R, Zhu X, Vaccaro HA, Shih NY, West RE. Benzimidazole-substituted (3-phenoxypropyl)amines as histamine H3 receptor ligands. Bioorg. Med. Chem. Lett. 18(18), 5032–5036 (2008).
  Medline CASGoogle Scholar
• 42 Yadav Y, MacLean ED, Bhattacharyya A et al. Design, synthesis and bioevaluation of novel candidate selective estrogen receptor modulators. Eur. J. Med. Chem. 46, 3858–3866 (2011).
  Medline CASGoogle Scholar
• 43 Nadri H, Pirali-Hamedani M, Moradi A et al. 5,6-Dimethoxybenzofuran-3-one derivatives: a novel series of dual acetylcholinesterase/butyrylcholinesterase inhibitors bearing benzyl pyridinium moiety. Daru 21(1), 15–23 (2013).
  Medline CASGoogle Scholar
• 44 Noushini S, Alipour E, Emami S et al. Synthesis and cytotoxic properties of novel (E)-3-benzylidene-7-methoxychroman-4-one derivatives. Daru 21(1), 31–40 (2013).
  Medline CASGoogle Scholar
• 45 Arab S, Sadat-Ebrahimi SE, Mohammadi-Khanaposhtani M et al. Synthesis and evaluation of chroman-4-one linked to N-benzyl pyridinium derivatives as new acetylcholinesterase inhibitors. Arch. Pharm. 348(9), 643–649 (2015).
  Medline CASGoogle Scholar
• 46 Katritzky AR, Kennewell PD, Snarey M. Steric requirements of sp²-hybridised lone electron pairs. Part II. The conformations of 2-(pyridylmethylene)-benzofuran-3(2H)-ones. J. Chem. Soc. B. 554–556 (1968).
  Google Scholar
• 47 Beney C, Mariotte A, Boumendjel A. An efficient synthesis of 4,6-dimethoxyaurones. Heterocycles 55(5), 967–972 (2001).
  CASGoogle Scholar
• 48 Detsi A, Majdalani M, Kontogiorgis CA, Hadjipavlou-Litina D, Kefalas P. Natural and synthetic 2′-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity. Bioorg. Med. Chem. 17(23), 8073–8085 (2009).
  Medline CASGoogle Scholar
• 49 Lipinski CA, Lombardo L, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3–26 (2001).
  Medline CASGoogle Scholar
• 50 RSCB Protein Data Bank. http://www.rcsb.org/pdb/home/home.do
  Google Scholar